C4 Therapeutics: director Kenneth Carl Anderson received 3,662 shares

What happened Kenneth Carl Anderson, a director of C4 Therapeutics, received 3,662 shares on Oct 1, 2026 as an award/grant (code A). The filing lists the price as $3.14 per share, for a total value of $11,499, and notes the shares were issued in lieu of cash compensation.

Key details

• Transaction date and price: Oct 1, 2026 — 3,662 shares at $3.14 per share; total $11,499.
• Form filed: Oct 2, 2026.
• Shares owned after the transaction: not specified in the provided filing.
• Relevant footnotes:
  • F1: Shares issued under the issuer's non-employee director compensation policy; reporting person elected to receive shares instead of cash.
  • F2: Price based on the closing market price on Oct 1, 2026.
  • F3–F7: Shares reported as held by trusts (Kenneth C. Anderson 2021 Irrevocable Trust; Kenneth C. Anderson 2015 Irrevocable Trust; Cynthia E. Anderson 2015 Irrevocable Trust; Kenneth C. Anderson Revocable Trust; Cynthia E. Anderson Revocable Trust). The reporting person disclaims beneficial ownership except to the extent of his pecuniary interest.
• Filing timeliness: no late filing indicated in the provided information.

Why it may matter

• This was an awarded grant as part of director compensation, not a market purchase.
• Shares are held in various trusts with a disclaimer of beneficial ownership except for pecuniary interest. A filing does not show why the insider traded or why the company acted.